Bio Pharmaceutics

Alexander V. Maksimenko, male, enzyme engineer of medical preparations, began his work in chemistry at Moscow State University, Chemistry Department where he received a Master of Science degree in 1975 and then Ph.D. in chemistry in 1978. He completed a Doctor of Science in biochemistry and cardiology in 1989 at USSR Cardiology Research Center. He has a long history of work at the Cardiology Center, Moscow beginning in 1978 to present. He is currently the Director of biochemical engineering laboratory, Professor in the Institute of Experimental Cardiology at Russian Cardiology Research-and-Production Complex, Moscow, Russia. Now he has published more than 200 papers and is the holder of over ten Russian and foreign patents. The thrombolytic enzyme compositions, modified enzyme derivatives for antioxidant therapy, hyaluronidase testing a microcirculation endothelial glycocalyx were researched and developed under his guidance. Recognized for his work, Professor Maksimenko is the recipient of medals of exhibition for national economy achievements, the prize winner for research scholarship, laureate of different national and international prizes and decrees of merit. He received membership in the International Commission on Pharmaceutical Enzymes (F.I.P.) in Ghent, Belgium and other International Scientific Societies.

His research interests are focused on therapeutic enzymes, polymeric drugs, dosage regimen, courses of enzyme therapy, drug targeting and therapeutic compositions.

Perry received his bachelors of arts degree in zoology with high honors from University of California, Santa Barbara. After graduation, he headed to Scripps Institution of Oceanography and obtained his Ph.D. in marine biology under David Epel in 1979. He then received a postdoctoral fellowship in the Department of Cell Biology in the laboratories of Drs. Bill Brinkley and Joseph Bryan at Baylor College of Medicine where he laid the foundation for his observations of abnormalities in cell structures. In 1982, Perry joined the faculty of Case Western Reserve University, where he currently holds an adjunct appointment. He is distinguished as one of the top Alzheimer’s disease researchers with over 800 publications, one of the top 100 most-cited scientists in neuroscience and behavior and one of the top 25 scientists in free radical research. Perry has been cited over 23,000 times and is recognized as an ISI highly cited researcher. Perry is editor for numerous journals and is editor-in-chief for the Journal of Alzheimers Disease. He is a fellow of the American Association for the Advancement of Sciences and past-president of the American Association of Neuropathologists, as well as a member of the Dana Alliance for Brain Initiatives. Perry is recognized internationally for his work. He is a Foreign Correspondent Member of the Spanish Royal Academy of Sciences and a Foreign Member of the Mexican National Academy of Sciences, and recent recipient of the National Plaque of Honor from the Republic of Panama Ministry of Science and Technology.

Our studies are focused on the mechanism of formation and physiological consequences of the cytopathology of Alzheimer disease. We have shown that oxidative damage is the initial cytopathology in Alzheimer disease. We are working to determine the sequence of events leading to neuronal oxidative damage and the source of the increased oxygen radicals. Our current studies focus on (i) the mechanism for RNA-based redox metal binding; (ii) the consequences of RNA oxidation on protein synthesis rate and fidelity; (iii) the role of redox active metals in mediating prooxidant and antioxidant properties; (iv) the signal transduction pathways altered in Alzheimer disease that allow neurons to evade apoptosis; and (v) mechanism of phosphorylation control of oxidative damage to neurofilament proteins

Panayiotis P. Constantinides received a University Diploma in Chemistry from Athens University in 1977 and PhD in Biochemistry from Brown University in 1983. He was a postdoctoral fellow in the Pharmacology Department and Associate Research Scientist in the Comprehensive Cancer Center of Yale University School of Medicine (1983 -1987). Dr. Constantinides since 2004 is the Founder and Principal of Biopharmaceutical & Drug Delivery Consulting, LLC based in Gurnee, IL and currently Affiliated Associate Professor of Pharmaceutical Sciences at Roosevelt University, College of Pharmacy, in Schaumburg, IL. Past industrial positions held included: Vice President of R&D with DOR BioPharma and Morton Grove Pharmaceuticals (2001-2004), Director of Research at SONUS Pharmaceuticals (1997-2000) and from 1987 to 1997 a number of R&D positions of increasing responsibilities with LipoGen, SmithKline Beecham Pharmaceuticals and Abbott Laboratories. He is inventor in 33 patents and patent applications, has authored more than 100 publications/book chapters/abstracts and he has been invited speaker at many national and international conferences, biotech and pharmaceutical companies and universities. Dr. Constantinides is AAPS Fellow, Vice Chair of the AAPS Formulation Design and Development Section, Past Chair of the Nanotechnology and Lipid-Based Drug Delivery Systems Focus Groups.

Drug Delivery Systems and Biopharmaceutics

Jasmine Musakhanian is Scientific & Marketing Director at the Pharmaceutical Division of Gattefossé USA. She has over 25 years of multi-disciplinary experience in excipient functionality and applications. A 1986 graduate of McGill University in human nutrition and food chemistry (MSc., Food Science) she first worked as research and teaching associate at McGill University. Later she held technical support positions with various excipient providers. Since joining the Gattefossé group in 1997, she has focused on lipid excipients and lipid based drug delivery systems for oral liquid and solid dosage forms as well as topical formulations. She is author of technical and scientific reviews; actively involved in scientific programming at AAPS and CRS; and is a frequently invited speaker at scientific meetings.

Formulation, Pharmaceutics, Drug Delivery,

Patrick Maurel spent 40 years in academia culminating as research director at Inserm. Patrick is world expert in the field of hepatology and has had a pivotal role in the development of primary cultures of human hepatocytes as screening tools used within the pharmaceutical industry. More recently, Patrick\'s research has been focused on the mechanisms of hepatitis C infection and on the use of stem cells as a potential biotherapy of liver diseases. Patrick has co-authored more than 180 international publications and is a fellow of several learned societies related to drug industries, drug metabolism, virology and hepatology.

drug metabolism, virology and hepatology.

Adam WG Alani completed his Ph.D in the field of Pharmaceutical Sciences on May 2007 from the University of Wisconsin-Madison under the guidance of the late Prof. Joseph R. Robinson. Dr. Alani completed his postdoctoral studies from the same institute in the field of design and synthesis of polymeric micelles for drug delivery and targeting under the guidance of Prof. Glen S. Kwon. Currently, he is an Assistant Professor of Pharmaceutical Sciences at the College of Pharmacy, Oregon State University. Dr. Alani’s research focuses on the development of new modalities for targeting angiogenesis in cancer and other disease states.

Designing biocompatible, biodegradable therapeutic polymers for specific disease states. Designing intelligent nanocarriers to meet specific therapeutic challenges.

Andrea Leone-Bay holds a PhD in Organic Chemistry and has worked in the pharmaceutical industry for over 25 years. She has published 45 manuscripts in peer-reviewed journals and is an inventor on 87 issued US patents. Her primary areas of expertise include chemistry and formulations research and development for protein and peptide delivery.

Drug delivery and development of several therapeutic compounds.

Dr. Noreddin received his Ph.D. University of the Pacific and research training at the Department of Medicine, Stanford University, CA. He had postdoctoral fellowship, University of Manitoba followed by an American College of Clinical Pharmacy fellowship. His research interest includes Pharmacoklinetic/Pharmacodynamic modeling of anti-infective therapy, clinical simulation and bacterial resistance in biofilm studies. Dr. Noreddin has outstanding records of scientific and academic accomplishments with multiple research funding, numerous publications in highly prestigious journals and various presentations in both national and international conferences. He served as a scientific reviewer for the NIH as well as other national and international research institutions.

1. Pharmacokinetic/Pharmacodynamic modeling of anti-infective and anti-cancer therapy 2. Clinical simulation and Monte Carlo analysis 3. Bacterial resistance in biofilm studies 4. Cancer epigenetic studies 5. Minority health care studies

Shengquan Liu completed his Ph.D in Medicinal Chemistry from Louisiana University, Monroe in 1997 and postdoctoral studies in Oklahoma State University and The University of Texas at Austin from 1997 to 2001. He was a senior research scientist at Albany Research Inc. from 1991 to 2005 and assistant professor in Touro University – California since 2006. He has published more than 14 papers in reputed journals, 7 US patents and contributed to 2 book chapters.

Pharmaceutical Sciences

Dr. Farid Menaa is an inter- and multi-disciplinary professional. Professor, Director and Consultant, he was awarded with a Master in Genetics (1999) and PhD in Medicine (Gerontology, Biochemistry and Biophysics) with high distinction from prestigious French universities (Paris, 2003). Dr. Menaa was a post-doctoral fellow in Oncology (San Diego, California, USA; 2004–2009), in Dermatology and Stem Cells (Wuerzburg, Germany; 2007–2009), in Hematology and Genomics (São Paulo, Brazil; 2010–2012). Dr. Menaa followed various formations (Medecine, Pharmacy, Chemistry, Nanotechnology, Bioinformatics, MBA...). Dr. Menaa was promoted as Chief Scientific Officer and Vice-President R&D at Fluorotronics, Inc. (CA, USA) for the period of 2009–1010. Dr. Menaa has a strong experience with teaching, consulting, research, collaborations in several countries. Dr. Menaa is a member of several prestigious organizations (medical and scientific societies), editor and reviewer of a number of esteemed journals worldwide. Dr. Menaa authored and co-authored more than 100 publications (including research and review articles, books and book chapters, proceedings, patents). Dr. Menaa is often invited as a speaker and chairman to reputed world congresses and offered speeches in various areas of medicine, sciences and technology. During his spare time, Dr. Menaa enjoys arts, sports and travelling.

Dr. Menaa´s R&D interests include the integration of innovative green techniques, technologies, methods and applications for personalized and translational medicine, in particular to improve the outcomes of cancer patients, stroke patients and to delay the anti-aging process while improving the life quality of the human beings.

Dr. Douroumis a Reader in Pharmaceutical Sciences in the Faculty of Engineering and Science at the University of Greenwich, UK. He obtained his BSc in Chemistry and PhD from the Department of Pharmacy at Patras University in Greece. He worked as a postdoc fellow (2004) at the Friedrich–Schiller University of Jena and as a Team Leader (2005) in Biolitec Pharma. He worked for Phoqus Pharmaceutical plc as a Senior Scientist (2005) while he joined the School of Sciences in 2007. He is member of the Board of the Academy of Pharmaceutical Sciences (APS) and he has joined the Editorial Boards of more than five international peer reviewed journal including the Wiley’s Editorial Board for the series in “Advances in Pharmaceutical Technology”. He has published more than 120 peer-reviewed publications, including 50 full papers, 4 book chapters and 2 books.

Development of novel drug delivery systems for cancer imaging and treatment (liposomes, solid lipid nanoparticles, mesoporous silica nanoparticles and conjugated quantum dots).